HitGen(SH:688222) Zheng Quan Zhi Xing·2025-06-29 16:17Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. has announced the termination of its major asset restructuring plan due to the inability to reach consensus on core terms with the counterparty [1][4]. Summary by Sections 1. Basic Situation of the Major Asset Restructuring - The company intended to acquire approximately 65% of the shares of Nanjing Haina Pharmaceutical Technology Co., Ltd. through a cash transaction, which would have made it the controlling shareholder of the target company [1][2]. 2. Main Work During the Restructuring Process - The company engaged professional intermediaries for due diligence and conducted multiple rounds of negotiations regarding the transaction plan, price, and performance commitments, while adhering to regulatory disclosure obligations [2][5]. 3. Reasons for Termination of the Restructuring - The termination was agreed upon due to the failure to reach consensus on key terms such as transaction plan, price, and performance commitments, despite active efforts from both parties [4][5]. 4. Decision-Making Process for Termination - The termination of the restructuring plan did not require submission for internal board or shareholder approval as it was still in the planning stage [5]. 5. Impact of Termination on the Company - The termination will not adversely affect the company's business operations or financial status, and there are no penalties for either party as no formal agreement was signed [5][6]. 6. Commitment Matters - The company commits not to plan any major asset restructuring for at least one month following the announcement [6]. 7. Other Notes - The company emphasizes that all information should be verified through its designated disclosure media, including Shanghai Securities Journal and the Shanghai Stock Exchange website [6].